Clinical trial NCT05119335: A Study of NKT2152, a HIF2α Inhibitor, in Patients with Advanced Clear Cell Renal Cell Carcinoma
Official title: Phase 1/2 Open Label Dose-escalation and Expansion Trial of NKT2152 an Orally Administered HIF2α Inhibitor to Investigate Safety Pharmacokinetics Pharmacodynamics and Clinical Activity in Patients with Advanced Clear Cell Renal Cell Carcinoma
Study type: INTERVENTIONAL
Overall status: ACTIVE_NOT_RECRUITING
Phase: PHASE1
PHASE2
Conditions: CcRCC
Clear Cell Renal Cell Carcinoma
Kidney Cancer
Kidney Neoplasms
Renal Cancer
Renal Neoplasms
Recurrent Renal Cell Carcinoma
Metastatic Renal Cell Carcinoma
Refractory Renal Cell Carcinoma
Advanced Renal Cell Carcinoma
Hypoxia
Renal Cell Carcinoma
Hypoxia Inducible Factor (HIF)
HIF2α Inhibitor
Hypoxia Inducible Factor 2 Alpha (HIF-2 Alpha)
Hypoxia Inducible Factor 2α (HIF-2α)
Clear Cell
Keywords: Hypoxia inducible factor (HIF)
HIF2α INHIBITOR
HIF1α
clear cell
Hypoxia inducible factor 2 alpha (HIF-2 alpha)
Hypoxia inducible factor 2α (HIF-2α)
Renal Cell Carcinoma (RCC)
Kidney Cancer
Lead sponsor: NiKang Therapeutics, Inc.
Sponsor class: INDUSTRY
First posted: 2021-11-15
Enrollment: 128
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: SEQUENTIAL
Intervention model description: Phase 1 dose escalation sequential; Phase 2 dose expansion randomized to 2 dosage levels
Primary purpose: TREATMENT

Brief summary: The goal of the Phase 1 portion is to identify the maximum tolerated dose (MTD) and/or the recommended doses for expansion (RDEs) of NKT2152. The Phase 2 portion will evaluate the efficacy of NKT2152 in ccRCC.

Detailed description: This is a Phase 1/2 open label multicenter study of NKT2152. Phase 1 is a first in human (FIH) dose escalation study in patients aged 18 years or older with clear cell renal carcinoma (ccRCC) who have exhausted available standard therapy as determined by the investigator.

Phase 1 is designed to determine the MTD and/or RDEs of NKT2152 as a single agent administered orally once daily. Depending on the tolerability and PK, additional dosing schedules may be tested. Phase 2 will evaluate the safety, pharmacokinetics and antitumor efficacy of NKT2152 in ccRCC patients. Patients will be randomized to one of two dosage levels selected for further evaluation.

Eligibility criteria: Patients must meet all of the following criteria to be enrolled in this study.

1. Has the ability to understand and willingness to sign a written informed consent form before the performance of any study procedures
2. Has locally advanced or metastatic ccRCC and has progressed during treatment, are relapsed, refractory and not amenable to curative therapy or standard therapy and has progressed during treatment with at least 1 prior therapeutic regimen
3. Must have measurable disease per the Response Evaluation Criteria in Solid Tumors version 1.1 (RECIST 1.1)
4. Is of age ≥ 18 years
5. Has an Eastern Cooperative Oncology Group (ECOG) performance status of 0-2
6. Has a life expectancy of ≥ 3 months
7. Has adequate organ function defined as follows:

   1. Bone marrow: ANC ≥ 1.0 × 10\^9/L; Hgb level ≥ 10 g/dL without transfusion or erythropoietin support within 2 weeks prior to first dose; platelet count ≥ 75,000/μL
   2. Hepatic: transaminase levels (AST/ALT) ≤ 2.5 × ULN (≤ 5 × ULN if liver metastases is present); total bilirubin (TBILI) ≤ 1.5 × ULN in the absence of Gilbert's disease
   3. Renal: serum creatinine level ≤ 2.0 × ULN or calculated creatinine clearance (CrCL) ≥ 40 mL/min (Cockcroft-Gault formula)
8. If a female patient of child-bearing potential, has a negative serum pregnancy test result within 7 days before first study drug administration
9. If a female patient, must be surgically sterile, must be post-menopausal, or must agree to use physician-approved method of birth control during screening, during the study, and for a minimum of 6 months after the last study drug administration; or if a male patient with a female partner, must agree to use physician-approved method of birth control during screening, during the study, and for a minimum of 6 months after the last study drug administration
10. Female patients of childbearing potential must meet all of the following criteria:

    1. Not pregnant (negative serum pregnancy test during Screening)
    2. Not breast feeding
    3. Willing to use a protocol-recommended method of contraception or to abstain from heterosexual intercourse from the start of treatment or until at least 6 months after the last dose of treatment. Note: A female patient is considered to be of childbearing potential unless she has had a hysterectomy, bilateral tubal ligation, or bilateral oophorectomy; has medically documented ovarian failure (with serum estradiol and follicle-stimulating hormone levels within the institutional laboratory postmenopausal range and a negative serum or urine beta human chorionic gonadotropin); or is menopausal (amenorrhea for 12 months).
11. Male patients who can father a child must meet all of the following criteria:

    1. Willing to use a protocol-recommended method of contraception or to abstain from heterosexual intercourse with females of childbearing potential from the start of treatment until at least 6 months after the last dose of treatment, and
    2. Willing to refrain from sperm donation from the start of treatment until at least 6 months after the last dose of treatment. Note: A male patient is considered able to father a child unless he has had a bilateral vasectomy with documented aspermia or a bilateral orchiectomy.
12. Able to swallow oral medications.
13. Ambulatory subjects need to take a six-minute walk test. Walking distance needs to be at least 400 meters and the change of oxygen saturation needs to be within 5% range.

Patients will be excluded from this study if they meet any of the following criteria.

1. Known symptomatic brain metastases requiring \> 10 mg/day of prednisone (or its equivalent). Patients with previously diagnosed brain metastases are eligible if they have completed their treatment, have recovered from the acute effects of radiation therapy or surgery prior to the start of NKT2152 treatment, fulfill the above steroid requirement for these metastases, and are neurologically stable based on central nervous system imaging ≥ 4 weeks after CNS-directed treatment.
2. Having one or more of the following conditions:

   1. A pulse oximetry reading less than 95% at screening;
   2. Any current requirement for intermittent or chronic supplemental oxygen;
   3. Any chronic lung condition which has required supplemental oxygen in the past;
   4. Evidence of impending airway compromise (such as endobronchial tumor, lymphangitic spread, significant extrinsic compression of major airway) per investigator;
   5. Ascites requiring drainage within 28 days prior to W1D1
3. History of another malignancy except for the following: adequately treated local basal cell or squamous carcinoma of the skin, in situ cervical cancer, adequately treated papillary noninvasive bladder cancer, other adequately treated Stage 1 or Stage 2 cancers currently in complete remission, or any other cancer that has been in complete remission for ≥ 2 years
4. Has failed to recover from the effects of prior anticancer therapy to baseline level or Grade 1 severity (except for alopecia) per NCI CTCAE; patients with treatable adverse effects such as hypothyroidism or hypertension may be enrolled if the adverse effect is controlled with treatment
5. Significant cardiovascular disease, including myocardial infarction, arterial thromboembolism, or cerebrovascular thromboembolism, within 6 months prior to start of NKT2152 treatment; symptomatic dysrhythmias or unstable dysrhythmias requiring medical therapy; angina requiring therapy, symptomatic peripheral vascular disease; New York Heart Association Class 3 or 4 congestive heart failure; ≥ Grade 3 hypertension (diastolic blood pressure ≥ 100 mmHg or systolic blood pressure ≥160 mmHg) despite adequate use of anti-hypertensives; or history of congenital prolonged QT syndrome or repeated demonstration of a QTc interval \> 480 ms; ejection fraction \< 40%; clinically significant pericardial or pleural effusion in the opinion of the investigator.
6. Has received prior investigational therapy or standard therapy within 5 half-lives of the agent or 4 weeks before the first administration of study drug, whichever is shorter
7. Has a bleeding diathesis or coagulopathy
8. Deep vein thrombosis (DVT)/pulmonary embolism are allowed as long as patient is not symptomatic and received 2 weeks or more of adequate anticoagulation
9. Has manifestations of malabsorption due to prior gastrointestinal (GI) surgery or GI disease
10. Has any other clinically significant cardiac, respiratory, or other medical or psychiatric condition that might interfere with participation in the trial or interfere with the interpretation of trial results
11. Has had major surgery within 4 weeks before first study drug administration; the following procedures are not considered to be major surgeries: thoracentesis, port placement, laparoscopy, thoracoscopy, bronchoscopy, endoscopic or ultrasonographic procedures, mediastinoscopy, skin biopsy, incisional biopsy, image-guided biopsy for diagnostic purposes, and routine dental procedures
12. Has known human immunodeficiency virus (HIV)
13. Has an active infection requiring systemic treatment
14. Is actively participating in another therapeutic clinical trial

Primary outcomes:
measure: Number of Participants with Dose Limiting Toxicity (DLT) events during the DLT monitoring period (first 21 days of dosing) in the Dose Escalation Phase (Phase 1)
timeFrame: 21 days
measure: Recommended Doses for Expansion (RDEs) Determined in the Dose Escalation Phase (Phase 1)
timeFrame: Approximately 2 years
measure: Objective Response Rate (ORR) determined by the Investigator in the Dose Expansion Phase (Phase 2)
timeFrame: Approximately 1 year
measure: Recommended Phase 2 Dose (RP2D)
timeFrame: Approximately 1 year
Secondary outcomes:
measure: Number of Participants with Adverse Events
timeFrame: Approximately 2 years
measure: Area under the plasma concentration time curve (AUC0-t) of NKT2152
timeFrame: Up to Day 22
measure: Area under the plasma concentration time curve (AUC0-∞) of NKT2152
timeFrame: Up to Day 22
measure: Maximum observed plasma concentration (Cmax) of NKT2152
timeFrame: Up to Day 22
measure: Time to maximum observed plasma concentration of NKT2152 (Tmax)
timeFrame: Up to Day 22
measure: Objective Response Rate (ORR) determined by the Investigator in the Dose Escalation Phase (Phase 1)
timeFrame: Approximately 1 year
measure: Duration of response (DOR)
timeFrame: Approximately 1 year
measure: Disease control rate (DCR) determined by the Investigator
timeFrame: Approximately 1 year
measure: Progression free survival (PFS)
timeFrame: Through study completion, an average of 2 years
measure: Overall survival (OS)
timeFrame: Through study completion, an average of 2 years
Other outcomes:
Locations:
city: Scottsdale
country: United States
facility: HonorHealth
state: Arizona
city: Los Angeles
country: United States
facility: UCLA
state: California
city: Denver
country: United States
facility: Sarah Cannon Research Institute
state: Colorado
city: Atlanta
country: United States
facility: Emory University
state: Georgia
city: Indianapolis
country: United States
facility: Indiana University Simon Comprehensive Cancer Center
state: Indiana
city: Iowa City
country: United States
facility: University of Iowa
state: Iowa
city: Bethesda
country: United States
facility: National Cancer Institute
state: Maryland
city: Boston
country: United States
facility: Dana Farber Cancer Institute
state: Massachusetts
city: Omaha
country: United States
facility: Nebraska Cancer Specialists
state: Nebraska
city: Oklahoma City
country: United States
facility: University of Oklahoma
state: Oklahoma
city: Portland
country: United States
facility: Oregon Health and Science University
state: Oregon
city: Houston
country: United States
facility: MD Anderson Cancer Center
state: Texas
city: Seattle
country: United States
facility: Seattle Cancer Care Alliance
state: Washington
Study officials:
References: